Lanza F, Campioni D, Moretti S, Dominici M, Punturieri M, Focarile E, Pauli S, Dabusti M, Tieghi A, Bacilieri M, Scapoli C, De Angeli C, Galluccio L, Castoldi G
Section of Hematology and BMT Unit, Department of Biomedical Sciences and Advanced Therapies, University Hospital, Ferrara, Italy.
Exp Hematol. 2001 Dec;29(12):1484-93. doi: 10.1016/s0301-472x(01)00726-3.
The aim of this study was to evaluate which CD34(+) cell subset contained in leukapheresis products could be regarded as the most predictive of long-term hematopoietic recovery after autologous peripheral blood stem cell transplantation (auto-PBSCT).
Based on data from 34 patients with hematologic malignancies, doses of CD34(+) cells and CD34(+) cell subsets, defined by the expression of HLA-DR, CD38, CD117 (c-kit/R), CD123 (alpha subunit of IL-3/R), CD133 (AC133), and CD90 (Thy-1) antigens, were correlated with the number of short-term (i.e., colony-forming cells [CFC]) and long-term culture CFC (LTC-CFC) (generated at week 5 of culture) and with the kinetics of hematopoietic engraftment following auto-PBSCT. The capacity of autologous stroma (AS), normal human bone marrow stroma, and M2-10B4 murine cell line to sustain CD34(+) cell growth was comparatively evaluated in the LTC assay.
Our data demonstrated that some of the most primitive progenitor subsets (CD34(+)CD117(-)HLA-DR(-), and CD34(+)CD38(+)HLA-DR(-)) showed the strongest correlation with LTC-CFC numbers generated within the AS, whereas no significant correlation was noted using normal bone marrow stroma. Multivariate analysis showed that the only CD34 cell subset independently associated with long-term (3 to 6 months) platelet engraftment after auto-bone marrow transplantation was the CD34(+)CD117(-)HLA-DR(-) phenotype; long-term erythrocyte engraftment was correlated with CD34(+)CD38(+)HLA-DR(-) cell content. The latter further influenced platelet engraftment in the first 3 months after auto-PBSCT. The most predictive parameters for neutrophil engraftment were CD34(+)CD38(+)HLA-DR(-) cell subtype and the total LTC-CFC quantity infused.
These data further support the hypothesis that the type of stromal feeders influences the frequency of LTC-CFC, possibly because they differ in their ability to interact with distinct subsets of hematopoietic stem cells. Furthermore, as the use of AS in LTC assay can mimic in vitro the human bone marrow microenvironment, it can be speculated that this culture system could be a useful means to study the kinetics of recovery of bone marrow stroma following chemotherapy and PBSCT. From these results, it can be concluded that some CD34(+) cell subsets appear to be more reliable predictors of long-term hematopoietic recovery rates than total CD34(+) cell quantity.
本研究旨在评估白细胞分离产品中所含的哪种CD34(+)细胞亚群可被视为自体外周血干细胞移植(auto-PBSCT)后长期造血恢复的最具预测性的指标。
基于34例血液系统恶性肿瘤患者的数据,根据HLA-DR、CD38、CD117(c-kit/R)、CD123(IL-3/R的α亚基)、CD133(AC133)和CD90(Thy-1)抗原的表达所定义的CD34(+)细胞剂量和CD34(+)细胞亚群,与短期(即集落形成细胞[CFC])和长期培养CFC(LTC-CFC,培养第5周产生)的数量以及auto-PBSCT后的造血植入动力学相关联。在长期培养试验中比较评估了自体基质(AS)、正常人骨髓基质和M2-10B4鼠细胞系维持CD34(+)细胞生长的能力。
我们的数据表明,一些最原始的祖细胞亚群(CD34(+)CD117(-)HLA-DR(-)和CD34(+)CD38(+)HLA-DR(-))与AS内产生的LTC-CFC数量显示出最强的相关性,而使用正常骨髓基质时未观察到显著相关性。多变量分析表明,自体骨髓移植后唯一与长期(3至6个月)血小板植入独立相关的CD34细胞亚群是CD34(+)CD117(-)HLA-DR(-)表型;长期红细胞植入与CD